134 related articles for article (PubMed ID: 37646148)
1. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Sidonio RF; Thompson AA; Peyvandi F; Stasyshyn O; Yeoh SL; Sosothikul D; Antmen AB; Maggiore C; Engl W; Ewenstein B; Tangada S
Expert Rev Hematol; 2023; 16(10):793-801. PubMed ID: 37646148
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
F1000Res; 2021; 10():1049. PubMed ID: 35136579
[No Abstract] [Full Text] [Related]
4. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Horling FM; Reipert BM; Allacher P; Engl W; Pan L; Tangada S
Blood Adv; 2024 Jun; 8(11):2726-2739. PubMed ID: 38564770
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
You CW; Baek HJ; Park SK; Park YS; Shin HJ; Engl W; Tangada S
Blood Res; 2019 Sep; 54(3):198-203. PubMed ID: 31730687
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
9. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
Sun SX; Frick A; Balasa V; Roberts JC
Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
[TBL] [Abstract][Full Text] [Related]
10. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
Klamroth R; Windyga J; Radulescu V; Collins PW; Stasyshyn O; Ibrahim HM; Engl W; Tangada SD; Savage W; Ewenstein B
Blood; 2021 Apr; 137(13):1818-1827. PubMed ID: 33150384
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
[TBL] [Abstract][Full Text] [Related]
14. Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab.
Sun SX; Crawford S
Expert Rev Hematol; 2023 Mar; 16(3):205-211. PubMed ID: 36655343
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
Lissitchkov T; Willemze A; Jan C; Zilberstein M; Katragadda S
Res Pract Thromb Haemost; 2023 May; 7(4):100176. PubMed ID: 37538505
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
Kenet G; Young G; Chuansumrit A; Matsushita T; Yadav V; Zak M; Male C
J Thromb Haemost; 2023 Nov; 21(11):3109-3116. PubMed ID: 37597724
[TBL] [Abstract][Full Text] [Related]
17. Inhibitor development, safety, and efficacy of Advate
Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
[TBL] [Abstract][Full Text] [Related]
20. Inhibitor development, safety and efficacy of Advate
Fukutake K; Taki M; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
Int J Hematol; 2019 Mar; 109(3):336-345. PubMed ID: 30604312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
